| Vol. 15.43 – 16 November, 2023 |
| |
|
|
| Predictive models of early- and late-stage placental transport were created using blastocyst-derived placental stem cells (PSCs) by modulating PSC differentiation and model vascularization. [Advanced Healthcare Materials] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| High-purity functional mitochondria with an intact structure were extracted from human umbilical cord-derived MSCs using the Dounce homogenization combined with ultracentrifugation. [Advanced Healthcare Materials] |
|
|
|
| The preventive effects of human amniotic membrane-derived MSC was assessed in humanized acute graft-versus-host disease models. Immunohistochemistry and RT-qPCR were used to evaluate intestinal barrier function. [Transplantation And Cellular Therapy] |
|
|
|
| Investigators explored the fetal insulin hypothesis theory further by testing the effects of GWAS-identified genetic variants related to insulin release and sensitivity on fetal growth and blood flow from week 20 of gestation to birth and on placental weight at birth. [Scientific Reports] |
|
|
|
| Researchers elucidated the inflammation-inhibiting efficacy of conditioned medium and extracellular vesicles derived from human trophoblast cells in lipopolysaccharide-induced human middle ear epithelial cells. [Scientific Reports] |
|
|
|
| The authors examined whether human umbilical cord-MSCs inhibited endothelial inflammation and improved endothelial function in Kawasaki disease (KD) through constructing cell and in vivo animal KD vasculitis models. [Inflammation] |
|
|
|
|
| Investigators propose prospective mechanisms of action of Wharton’s jelly-MSCs that may be mediating their observed capability to preserve β-cell function and prevent type 1 diabetes progression and provide recommendations for further investigations in clinical settings. [Stem Cells Translational Medicine] |
|
|
|
|
| Mirvie announced the completion of enrollment of its landmark 10,000 person research study for pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine. [Mirvie] |
|
|
|
|
| February 8 – 11, 2024 Cancun, Mexico |
|
|
|
|
|
| Applied Stem Cell – Milpitas, California, United States |
|
|
|
| University of California – Los Angeles, California, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| National University of Singapore – Singapore, Singapore |
|
|
|
| University of Turku – Turku, Finland |
|
|
|
|